Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Study of 609A in Advanced Solid Tumors
NCT03950297Phase 1Unknown
- Sponsor
- 3S Guojian Pharmaceutical
- Start
- May 2019
- Primary completion
- Oct 2020
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of 609A in solid tumor, sponsored by 3S Guojian Pharmaceutical. Primary endpoints: Treatment-Emergent Adverse Events at 90 days and Maximum Tolerated Dose at 90 days. Status: unknown.
02
Drugs
609A
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT03950297.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03950297.